Similar to other countries, anxiety-related disorders are common in Iran (
1,
2). According to the findings of the Iranian Mental Health Survey (
1), the 12-month prevalence of anxiety disorder is 15.6%. The 12-month and lifetime prevalence estimates of anxiety disorders in the United States are 18.1 (
3) and 28.8% (
4), respectively. While in 6 European countries (Belgium, France, Italy, Germany, Netherlands, and Spain) these were around 6.4 and 13.6%, respectively (
2). Anxiety disorders, on the one hand, have long-term effects on functional areas, and, on the other, often co-occur with other psychiatric and medical diseases (
5,
6). Considering the high prevalence of anxiety disorders and their functional consequences (
7), measures are needed in an assessment-based manner to evaluate anxiety disorders in various clinical and research settings (
8,
9).
Validated measures are often needed in a comprehensive assessment of anxiety (
10). Multiple measures have been developed and validated for assessing anxiety during the last decades (
10). Many of these measures assess the severity of anxiety based on the frequency of related symptoms, and enough attention is not paid to the functional impairments caused by anxiety. Simultaneously, it is important to monitor how anxiety affects the patient’s daily activities (
11).
Insufficient attention to functional impairments caused by anxiety may decrease the utility of scales for measuring the global effects of treatment (
12). Therefore, measures are needed to evaluate both severity and functional impairment. Meanwhile, measures should be short enough to be used in busy clinical settings. In recent decades, a number of well-known self-report measures of anxiety have been validated in Iran, including the Beck anxiety inventory (BAI) (
13) and state-trait anxiety inventory (STAI) (
14). Most of their items ask subjects about the presence of the symptoms and do not explore the functional impairments caused by anxiety-related symptoms. In addition to the above measures, other measures have also been validated that are related to functional impairment, such as the work and social adjustment scale (WSAS) (
15) and Sheehan disability scale (SDS) (
16). These measures exclusively ask subjects about functional impairment or disability and have no item about the frequency or severity of the experienced symptoms.
Recently, Norman and colleagues (
11) have developed the overall anxiety severity and impairment scale (OASIS). The OASIS is a 5-item self-report scale designed to assess functional impairment caused by anxiety symptoms as well as their frequency and severity. Specifically, the OASIS was developed to meet the need for an anxiety measure that could (a) measure directly the clinical severity and functional impairment, (b) report transdiagnostically the severity of any anxiety disorder, and (c) be short enough (
17). To date, this scale has been translated into Japanese (
18), Spanish (
19,
20), and Dutch (
12), and its psychometric properties have been investigated in three studies on the college student populations (
8,
11,
21) and in eight studies on the outpatient populations (
8,
12,
17-
20,
22,
23). These studies supported its one-factor structure and showed that it has robust reliability and validity. The applicability of this scale for various clinical and subclinical levels of anxiety and its specific emphasis on the functional impairment caused by anxiety symptoms distinguish it from the more conventional, longer anxiety measures (
11,
12).